ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CERS / dividends
BWAY (44) SSII (30) RCEL (46) DCTH (59) ⌘ Pro Terminal →

Cerus Corporation (CERS) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.28 -6.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.25

Cerus Corporation (CERS) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $459.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CERS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cerus Corporation (NASDAQ: CERS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $2.28 (-6.56% 1D, market cap $459.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CERS ranks #885 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CERS compare to BWAY and SSII in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), CERS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.5%. By comparison, BWAY (BrainsWay Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $455.9M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $471.1M). Among the 5-stock peer group, CERS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CERS?
▼

Per CERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001020214), Cerus Corporation generated $233.8M in revenue (+16.1% YoY), -$15.6M in net income, and $1.1M in free cash flow against $221.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.25 (-1.37%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (4)Whales (5)SEC (8)Macro (5)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-14% Base Target
$4 Bull$2 Base$2 Bear
📬 FREE CERS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CERS)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY CERS SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9

▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (19% of score)

20D Institutional Volume Accumulation (±8.1% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
19
Grade E$2.26+2.2% Next Q
Q2 (-2Q)
22
Grade E$2.31+3.9% Next Q
Q3 (-1Q)
24
Grade E$2.40-5% Next Q
Current
27
Grade E$2.28-10.3% Hist 90D α
Trajectory: E (19) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CERS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CERS currently carries a cautious 27/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.45) and Max Pain ($2.39) forces dealer call-delta covering toward $3.64.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CERS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CERS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (9.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $24,782

Est. Year-10 Shareholder Yield: $149/yr
$10.9K
Yr 1
$12.0K
Yr 2
$13.1K
Yr 3
$14.4K
Yr 4
$15.7K
Yr 5
$17.2K
Yr 6
$18.9K
Yr 7
$20.7K
Yr 8
$22.6K
Yr 9
$24.8K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CERS)

  • ✓Walkthrough of CERS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.18%📐 WEDGE COMPRESSION COIL
2026-11-03O $2.44H $2.44L $2.28C $2.28VOL 1.50M
RES: $2.44SUP: $2.13SMA50: $2.45SMA200: $2.45
$3.59$3.10$2.61$2.13$1.64RES $2.44SUP $2.13$2.282026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CERS Butterfly Map → + Track CERS →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +16.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CERS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CERS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CERS)

Health Care Rank #885 of 1016 ⚔️ BWAY vs CERS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CERS vs. BWAY, SSII, RCEL, DCTH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cerus Corporation (CERS) ranks #885 by composite RQD confidence (27/100, grade E) and #458 by equity capitalization ($459.5M). Within this direct 5-issuer industry benchmark cohort, CERS leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with CERS at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CERS ACTIVE
Cerus Corporation
E 27/100 — — -15.5% -6.56% $459.5M Benchmark Subject
BWAY
BrainsWay Ltd.
D 44/100 — — — -4.78% $455.9M /bway-vs-cers →
SSII
SS Innovations International Inc.
E 30/100 — 46.0% -18.5% -1.26% $471.1M /ssii-vs-cers →
RCEL
Avita Medical Inc.
D 46/100 — 82.1% -35.0% -6.34% $484.0M /rcel-vs-cers →
DCTH
Delcath Systems Inc.
C- 59/100 — 86.2% 0.8% -4.10% $487.2M /dcth-vs-cers →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001020214

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cerus Corporation (CERS) reported GAAP revenue of $233.8M (+16.1% vs. FY2024 revenue of $201.3M , and +25.2% cumulative change since FY2023) , GAAP net income of -$15.6M, operating cash flow of $4.8M, and free cash flow of $1.1M (-87.0% YoY). On the balance sheet, CERS closed FY2025 with $221.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $233.8M -$15.6M $4.8M $1.1M $221.9M —
FY2024 (FY) 2024-12-31 $201.3M -$20.9M $11.4M $8.5M $200.9M —
FY2023 (FY) 2023-12-31 $186.8M -$37.5M -$43.2M -$43.2M — —

3. CERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cerus Corporation (NASDAQ: CERS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $2.28 (-6.56% 1D, market cap $459.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CERS ranks #885 in composite RQD confidence.

How does CERS compare to BWAY and SSII in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CERS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.5%. By comparison, BWAY (BrainsWay Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $455.9M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $471.1M). Among the 5-stock peer group, CERS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CERS?

Per CERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001020214), Cerus Corporation generated $233.8M in revenue (+16.1% YoY), -$15.6M in net income, and $1.1M in free cash flow against $221.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CERS trading relative to its 50-day, 200-day, and 52-week technical levels?

CERS last traded at $2.28 (-6.56% on volume of 1,503,459 shares), positioning the stock -6.94% below its 50-day simple moving average ($2.45) and -6.94% below its 200-day simple moving average ($2.45). Across its 52-week range of $1.38 to $3.47, CERS sits at the 43.1% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.1% ($2.10 to $2.46).

CERS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does CERS pay a dividend and is it safe?

Cerus Corporation (CERS) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: CERS RQD Cockpit CERS 12M Forecast CERS Earnings & Move CERS Dividends & DRIP CERS Insiders & 13F CERS Whale Options CERS Profit Sankey CERS News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CERS — Cerus Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:35:54Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CERS scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4 / 20 (ROIC -15.5%; FCF yield 0.23%), Whale 13F Flow at 8 / 20 (institutional accumulation and options positioning), Insider Conviction at 5 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8 / 20 (Altman Z 0.2; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is Fundamental Cash Engine, which means the company's return on invested capital and free-cash-flow yield are the primary drag on the score. For a prospective investor evaluating the stock today, the implication is that the rating framework flags elevated forensic and cash-generation risk, with the low Altman Z-Score as the most prominent balance-sheet concern. Upside drivers within this framework are limited to the moderate institutional and balance-sheet readings; valuation tradeoffs cannot be fully assessed because P/E and EV/EBITDA are not available in source data.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$233.8M$-8.7M$-15.6MN/A$1.1M$20.0MN/A
FY 2024$201.3M$-14.2M$-20.9MN/A$8.5M$20.3MN/A
FY 2023$186.8M$-30.1M$-37.5MN/A$-43.2MN/AN/A

Per the SEC financials, revenue rose from $186.8M in FY 2023 to $233.8M in FY 2025 while net losses narrowed from $-37.5M to $-15.6M. The per-market-data operating margin is -3.7%, net margin is -6.7%, and gross margin is 0%, with ROIC at -15.5%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5; the low Altman Z-Score signals elevated distress risk, while the Piotroski reading is moderate. Reported FY 2025 cash of $20.0M and FY 2025 FCF of $1.1M provide limited liquidity cushion against continued operating losses.

Recent Catalysts & News Wire Analysis

Per the news wire, six items reference CERS, all tagged with a YELLOW light and MARKET WIRE impact label. Headlines include a Yahoo Finance UK market report, a MarketBeat analyst-opinion piece, a MarketScreener notice that Cerus will release Q3 2026 financial results on November 2, 2026, a Stock Titan item describing a workshop on treated platelets and a clotting product, a Simply Wall St penny-stock roundup, and an ad-hoc-news.de item citing a November 5, 2026 earnings date and a USD 63.25 million estimate. The Q3 2026 results release is the most time-sensitive catalyst in the source set. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals.

Open Questions

  • What are the reported EPS, P/E, and EV/EBITDA figures, given that these fields are absent from the source data?
  • What is the company's reported debt balance for FY 2024 and FY 2025, given that debt is recorded as N/A for each period?
  • What drove the FY 2025 operating loss of $-8.7M and the cash balance trend between FY 2024 and FY 2025?
  • What were the actual results disclosed in the Q3 2026 release scheduled for November 2, 2026, relative to the USD 63.25 million estimate?
  • Who are the company's principal products, customers, and competitors, since the business description is not available in source data?

CERS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cerus Corporation (CERS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CERS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CERS Bull vs. Bear Conversation Board — What's Your Call at $2.28?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CERS 🐻 67% BEARISH CONVICTION
1. Pick Your Side on CERS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.15 (-11.9%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CERS (E • RQD 30/100) a Buy at $2.44?

Welcome to the CERS (Cerus Corporation) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.03 (-16.8%)
Spot @ $2.44

Pump the brakes on CERS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CERS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cerus Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.93 (+20.1%)
Spot @ $2.44

CERS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CERS, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $2.44 (52-wk range $1.38 - $3.47), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%